Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma

Elisa Oricchio1, Hans-Guido Wendel

  • 1Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Cell Cycle (Georgetown, Tex.)
|February 24, 2012
PubMed

Insights

Researchers identified a tumor suppressor, soluble ephrin receptor A7 (EPHA7), lost in lymphoma. Antibody-based delivery restored this suppressor in cancer cells, offering new therapeutic avenues for cancer treatment.

Area of Science:

  • Genomics
  • Cancer Biology
  • Immunotherapy

Background:

  • Genomic data offers potential for novel cancer therapies but remains largely untapped.
  • Identifying clinically relevant genomic alterations is crucial for therapeutic development.

Purpose of the Study:

  • To mine cancer genomic data for clinically actionable information.
  • To identify novel tumor suppressors and develop targeted delivery strategies.

Main Methods:

  • Cross-comparison of cancer genomic data with unbiased genetic screening results.
  • Prioritization of genomic alterations for functional validation.
  • Development of antibody-based delivery systems for in situ restoration of tumor suppressors.

Main Results:

  • Identification of a soluble variant of ephrin receptor A7 (EPHA7) as a tumor suppressor.
  • Demonstration that EPHA7 is lost in lymphoma.
  • Successful in situ restoration of EPHA7 using antibody-based delivery.

Conclusions:

  • The strategy of integrating genomic data with genetic screens effectively identifies tumor suppressors.
  • Soluble EPHA7 is a novel tumor suppressor implicated in lymphoma.
  • Targeted delivery of tumor suppressors represents a promising therapeutic strategy for cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...